Acumen Pharmaceuticals (ABOS) Current Assets (2020 - 2026)

Acumen Pharmaceuticals has disclosed Current Assets across 7 years of filings, most recently posting $115.5 million for Q2 2026.

• In Q2 2026, Current Assets fell 22.16% year-over-year to $115.5 million; the TTM figure through Jun 2026 stood at $115.5 million (down 22.16% YoY), while the FY2025 annual figure was $122.3 million, down 31.44% from the prior year.
• Current Assets came in at $115.5 million for Q2 2026 at Acumen Pharmaceuticals, down from $133.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $266.9 million in Q2 2024 to a low of $115.5 million in Q2 2026.
• Average Current Assets over 5 years is $180.0 million, with a median of $179.3 million recorded in 2022.
• Year-over-year, Current Assets surged 170.72% in 2022 and sank 44.4% in 2025.
• Over 5 years, Current Assets stood at $180.3 million in 2022, then soared by 36.76% to $246.6 million in 2023, then retreated by 27.7% to $178.3 million in 2024, then tumbled by 31.44% to $122.3 million in 2025, then declined by 5.51% to $115.5 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $115.5 million in Q2 2026, $133.1 million in Q1 2026, and $122.3 million in Q4 2025.